Supplement to the Journal of Family Practice

Available at jfponline.com

Vol 59, No 9, Suppl 1 / September 2010

Distinguishing among incretin-based therapies

S3  Introduction

S5  Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies

S10  Glucose-lowering effects of incretin-based therapies

S20  Safety, tolerability, and nonglycemic effects of incretin-based therapies

S28  Patient education and self-management

This supplement was sponsored by the Primary Care Metabolic Group and the Primary Care Education Consortium and is supported by a grant from Novo Nordisk Inc. It was edited and peer reviewed by The Journal of Family Practice.

Copyright © 2010 Quadrant HealthCom Inc.

www.PCEConsortium.org  www.PCMG-us.org

Distinguishing among incretin-based therapies

S3  Introduction

S5  Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies

S10  Glucose-lowering effects of incretin-based therapies

S20  Safety, tolerability, and nonglycemic effects of incretin-based therapies

S28  Patient education and self-management

This supplement was sponsored by the Primary Care Metabolic Group and the Primary Care Education Consortium and is supported by a grant from Novo Nordisk Inc. It was edited and peer reviewed by The Journal of Family Practice.

Copyright © 2010 Quadrant HealthCom Inc.

www.PCEConsortium.org  www.PCMG-us.org
Distinguishing among incretin-based therapies

FACULTY AND AFFILIATIONS

R. Keith Campbell, PharmD, MBA, CDE
Distinguished Professor in Diabetes Care and Pharmacotherapy
Department of Pharmacotherapy
Washington State University College of Pharmacy
Pullman, Washington

Michael E. Cobble, MD, FNLA
Director
Canyons Medical Center
Sandy, Utah
Adjunct Faculty
University of Utah School of Medicine
Salt Lake City, Utah

Timothy S. Reid, MD
Department of Family Medicine
Mercy Diabetes Center
Janesville, Wisconsin

Mansur E. Shomali, MD, CM
Clinical Associate Professor of Medicine
University of Maryland School of Medicine
Associate Medical Director
Diabetes and Endocrine Center
Union Memorial Hospital
Baltimore, Maryland

FACULTY DISCLOSURES

Dr Campbell has disclosed that he is on the advisory board for Daiichi-Sankyo and the speakers bureau for Eli Lilly and Co.

Dr Cobble has disclosed that he is on the advisory board for Abbott Laboratories, AstraZeneca, and Eli Lilly and Co and the speakers bureau for Abbott Laboratories, AstraZeneca/ Bristol Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, and Novo Nordisk Inc.

Dr Reid has disclosed that he is on the advisory board and speakers bureau for Amylin Pharmaceuticals, Medtronic, Novo Nordisk Inc, and sanofi-aventis.

Dr Shomali has disclosed that he is on the advisory board for Novo Nordisk Inc and the speakers bureau for Amylin Pharmaceuticals, Eli Lilly and Co, sanofi-aventis, and Takeda Pharmaceuticals.

SPONSOR DISCLOSURE STATEMENT

The content collaborators at the Primary Care Education Consortium report that there are no existing financial relationships to disclose.

FACULTY HONORARIA BORUM DISCLOSURE AND EDITORIAL ASSISTANCE

Each author received editorial assistance from the Primary Care Education Consortium and WriteHealth, LLC in the development of this activity. They also received an honorarium from the Primary Care Education Consortium.

LEARNING OBJECTIVES

After reading this case-oriented supplement, clinicians should be better able to:

• Interpret physiologic and clinical data showing the role of incretin hormones in the control of glucose homeostasis
• Differentiate between the effects of glucagon-like peptide (GLP)-1 agonists and dipeptidyl peptidase (DPP)-4 inhibitors on indices of blood glucose
• Differentiate between the effects of GLP-1 agonists and DPP-4 inhibitors on weight and other nonglycemic parameters
• Identify the most common safety and tolerability issues associated with incretin-based therapies
• Describe patient case scenarios in which the diabetes care team can communicate information to improve patient outcomes
• Describe patients who may benefit from incretin therapy

STATEMENT OF SPONSORSHIP AND SUPPORT

This program is sponsored by the Primary Care Metabolic Group and the Primary Care Education Consortium and is supported by a grant from Novo Nordisk Inc.
The "treat to target" approach is to quickly achieve the target glycosylated hemoglobin (AIC) goal of <7% in most people, and then intensify or change therapy as needed to maintain glycemic control.

Results of an online survey demonstrate uncertainty regarding the clinical differences between glucagon-like peptide (GLP-1) agonists and dipeptidyl peptidase (DPP)-4 inhibitors.

The increasingly important roles of the GLP-1 agonists and DPP-4 inhibitors stem from their overall good efficacy and safety profiles compared with other treatment options.
There are many issues with regard to providing comprehensive care to patients with T2DM that could be covered in this supplement. For example, as described in the ADA standards of care, the risks of other diseases, such as dyslipidemia, hypertension, and coronary heart disease, must also be considered in management of these patients. Glucose control remains a principal concern, however, and is the primary focus of this supplement.

Driven by results of the February 2010 online survey, this supplement builds upon the 2 previous supplements on incretin-based therapies to address 4 key areas:

• The pathophysiology of T2DM and the unique role of incretin hormones
• Glycemic control differences among available incretin-based agents
• Nonglycemic differences among available incretin-based agents
• Patient education regarding incretin-based therapies to promote patient self-management, with examples of patient cases for which incretin-based therapy is an option

The discussion will take a practical, problem-oriented approach by following 3 cases:

Case 1
A 53-year-old man was diagnosed with T2DM 6 weeks ago, at which time lifestyle intervention was recommended and treatment with metformin 500 mg twice daily was initiated. The patient began to experience severe diarrhea within a few days of beginning metformin. The diarrhea improved over the next 2 to 3 weeks, but he still experiences 1 or 2 episodes every few days. As a result, he does not want to continue taking metformin.

At diagnosis, the patient’s A1C level was 7.5% and his fasting plasma glucose was 158 mg/dL. He is 6-ft 2-in tall, 236 lb, with a body mass index of 30 kg/m² and blood pressure of 123/78 mm Hg. The patient works full-time as a building contractor, and he is a current smoker. He has hypertriglyceridemia (266 mg/dL), which is being treated with a fibrate.

Case 2
A 47-year-old man was diagnosed with T2DM 2.5 years ago. His A1C level was 8.8%. He had a good response with lifestyle intervention and metformin 1000 mg twice daily, losing 17 lb over 1.5 years. During that time, his A1C level dropped to 7.2%. Six months ago, treatment with pioglitazone 15 mg was started because his A1C level had risen to 7.8%. His current A1C is 7.0%. He is upset because he has since gained 6 lb, mostly edema, which has raised his blood pressure to 138/87 mm Hg. He refuses to take a diuretic, because hydrochlorothiazide, which was prescribed for essential hypertension, caused him to urinate more often. He wants to discontinue pioglitazone so he will lose weight and regain control of his blood pressure.

The patient is 5-ft 9-in tall, 237 lb, with a body mass index of 35 kg/m². He works full-time as an office manager. He has essential hypertension, which is being treated with lisinopril and metoprolol.

Case 3
A 68-year-old woman was diagnosed with T2DM 5 years ago. Her A1C value was 8.7%. She was initially managed with lifestyle intervention, but 1 year after diagnosis, treatment with metformin 500 mg twice daily was initiated, and the dose was titrated to 1000 mg twice daily a year later. On this regimen, her A1C level dropped to 7.1%, but 1.5 years later, it had increased to 8.3%. At that time, glyburide 5 mg once daily was added to her treatment regimen and titrated to 10 mg once daily. Mild renal insufficiency (CrCl₉₀, 58 mL/min) was identified at today’s visit. Her current A1C is 7.4%.

The patient is 5-ft 3-in tall, 148 lb, with a body mass index of 26 kg/m² and blood pressure of 122/76 mm Hg. She works part-time as a librarian. She has peripheral arterial disease, which is being treated with aspirin, clopidogrel, and atorvastatin. She also has osteoporosis, which is being treated with ibandronate.

These cases, which represent various stages of disease progression, present important decision points regarding how to initiate or modify therapy. For each of these decision points, many factors must be considered, including underlying pathophysiology, comorbidities, A1C-lowering ability, and previous treatment. Other factors to consider are the safety of available agents, including the risk of hypoglycemia; tolerability; and nonglycemic effects, such as on weight, lipids, and blood pressure.

References
Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies

R. Keith Campbell, PharmD, MBA, CDE; Michael E. Cobble, MD, FNLA; Timothy S. Reid, MD; Mansur E. Shomali, MD, CM

Introduction
The pathophysiology of T2DM and the incretin system have been described in considerable detail in previous *Journal of Family Practice* supplements.1,2 In this article, we will briefly review the multiple pathophysiologic mechanisms known to be involved in T2DM, with a focus on the incretin system, to gain a better understanding of the disease progression affecting our 3 patients presented in the supplement introduction.

The central roles of insulin resistance and pancreatic β-cell dysfunction (insulin deficiency) in the pathogenesis of T2DM have been recognized for decades. But other causes of T2DM have been identified, including:

- Altered glucose release and disposal
- Altered glucagon secretion
- Impaired incretin response
- Rapid gastric emptying
- Impaired satiety

While there is a link between insulin resistance and pancreatic β-cell failure,3 the extent to which other causes interact is only beginning to be recognized. With a better understanding of the multifactorial pathogenesis of T2DM, however, has come additional treatment options and the opportunity for a more individualized and complementary approach to treatment.

Insulin resistance and pancreatic β-cell dysfunction
T2DM is a progressive disease characterized by worsening hyperglycemia,4 caused in part by insulin resistance and deterioration in pancreatic β-cell function. Insulin resistance appears to result from a complex interaction between visceral fat and the immune system that results in a state of chronic inflammation. Proinflammatory proteins secreted primarily from visceral fat block the action of insulin in adipocytes.5 Elevated levels of free fatty acids, which are common in obesity, further promote insulin resistance.6

Pancreatic β-cell dysfunction occurs progressively over a decade or more until β-cells are no longer capable of secreting sufficient insulin. Data from several studies suggest that, on average, 50% to 80% of β-cell function has been lost at the time of diagnosis of T2DM.7-9 The extent of pancreatic β-cell dysfunction is important for 2 reasons. First, medications that act by stimulating the β-cell to secrete insulin lose their effectiveness over time, as shown in the
UK Prospective Diabetes Study (UKPDS)\textsuperscript{7} and, more recently, in A Diabetes Outcome Progression Trial (ADOPT).\textsuperscript{10} Second, since only 20\% to 50\% of pancreatic β-cell function remains at the time of diagnosis, preserving β-cell function would likely be beneficial for long-term glycemic control.

But there is no time to waste following diagnosis of T2DM. The Belfast Diet Study,\textsuperscript{8} a 10-year prospective clinical trial of 432 newly diagnosed persons with T2DM treated with intensive lifestyle management, suggested that β-cell decline occurs in 2 phases. Beginning well before diagnosis, the annual rate of decline in β-cell function during the first phase, \(≥15\) years prediagnosis, is about 2\%, while during the second phase, beginning about 3 years postdiagnosis, the annual rate of decline in β-cell function accelerates to 18\% (\textbf{FIGURE 1}). This second phase appears to result from a combination of steadily increasing β-cell death rate and decreasing replication rate.\textsuperscript{8}

\textbf{Case 1:} A 53-year-old man newly diagnosed with T2DM who has tolerated metformin poorly

\textbf{Case 2:} A 47-year-old man diagnosed with T2DM several years ago who has experienced edema and weight gain on pioglitazone

\textbf{Case 3:} A 68-year-old woman with longstanding T2DM who has failed dual oral therapy and has microvascular complications

\textbf{Considering insulin resistance and pancreatic β-cell dysfunction in our 3 cases}
- Newly diagnosed with T2DM, the patient in Case 1 probably has 20\% to 50\% of his β-cell function remaining; preservation of β-cell function would be desirable, especially before he

\textbf{FIGURE 1} Phases of decline in pancreatic β-cell function\textsuperscript{a}

The results of a spline function model showing 2 phases of decline in pancreatic β-cell function. The spline function model simultaneously optimizes several variables affecting β-cell function.

HOMA %B, homeostasis model of assessment–percent β-cell function.

reaches the second phase of decline in β-cell function, about 3 years after diagnosis
• Diagnosed with T2DM about 2.5 years ago and not previously treated with a secretagogue, the patient in Case 2 has some β-cell function remaining; however, he is likely close to entering the second phase of steep decline in β-cell function observed in the Belfast Diet Study; in addition, insulin resistance related to his obesity must be addressed, as his obesity serves to stimulate pancreatic β-cells to secrete more insulin
• The Case 3 patient, diagnosed with T2DM about 5 years ago, is probably in the second phase of steep decline in β-cell function and has limited β-cell function remaining; furthermore, she has failed dual oral therapy that included almost 2 years of treatment with glyburide

The incretin system and GLP-1
As discussed in greater detail in a previous Journal of Family Practice supplement,1 the incretin system is integrally involved in glucose homeostasis. Glucose-dependent insulino tropic polypeptide (GIP) and GLP-1 are the 2 most important incretin hormones secreted in response to food ingestion. Patients with T2DM are resistant to GIP, which contributes to the impaired incretin response. In animal models and humans, GLP-1, the most clinically important incretin hormone, has been shown to:

• Increase insulin biosynthesis in a glucose-dependent manner through direct activation of receptors on islet β-cells and via the vagus nerve11-13
• Inhibit glucagon secretion in a glucose-dependent manner through direct activation of receptors on islet α-cells12,14,15
• Slow gastric emptying16
• Promote satiety17,18
• Promote proliferation, increase differentiation, and prolong survival of β-cells19-21
• Improve myocardial function22

The actions of endogenous GLP-1 are short-lived, as GLP-1 undergoes rapid degradation by the enzyme DPP-4. To overcome this rapid degradation, 2 treatment approaches have been taken. Injectable GLP-1 agonists, which are resistant to the enzymatic action of DPP-4, have been developed. Oral DPP-4 inhibitors, which allow for prolonged physiologic actions of endogenous GLP-1, also have been developed. Because of the pharmacologic levels of GLP-1 activity achieved, GLP-1 agonists have better glucose-lowering efficacy and also promote weight loss compared with DPP-4 inhibitors.23-26

Impaired incretin effect in T2DM
Until recently, it was thought that secretion of GLP-1 in response to ingestion of a meal in people with T2DM was significantly impaired compared with that in healthy controls (P<.001).27,28 Recent investigation, however, found that the GLP-1 levels in patients with T2DM did not decrease after oral ingestion of glucose or a mixed meal. The secretion of GIP, on the other hand, increased following oral ingestion of a mixed meal but not of glucose.29 These observations suggest that the unaltered secretion of GLP-1 in people with T2DM may be insufficient to make up for the diminished insulino tropic activity of GIP in people with T2DM. Consequently, pharmacologic levels of GLP-1 would be necessary to restore the insulino tropic actions of the incretin system.30

Incretin effects on the pancreatic β-cell and insulin resistance
Animal studies have indicated that GLP-1 has the ability to preserve β-cell function by suppressing β-cell apoptosis and stimulating neogenesis and proliferation.31,32 Several trials in people with T2DM have shown that administration of a GLP-1 agonist (exenatide or liraglutide) for up to 52 weeks either as monotherapy or added on to existing therapy results in significant improvement in pancreatic β-cell function.33-39 One trial involving patients whose treatment with metformin had not provided glycemic control showed a significant increase in first- and second-phase glucose-stimulated C-peptide secretion, both markers of β-cell function, with exenatide (1.53- and 2.85-fold, respectively; P<.0001) compared with insulin glargine.34 A 26-week trial found that the addition of exenatide or liraglutide to metformin, a sulfonylurea, or both resulted in improvement in β-cell function, as determined by the homeostasis model of assessment–β-cell function (HOMA-B); the improvement was significantly greater with liraglutide than with exenatide (32% vs 3%; P<.0001).37 The greater improvement in β-cell function may be a reflection of the greater lowering of fasting plasma glucose with liraglutide than with exenatide.

Clinical trials with DPP-4 inhibitors (saxagliptin or sitagliptin) also have shown significant improvement in β-cell function (up to 16%; P<.05) over 24 weeks.40-43 Generally, however, there are fewer data regarding
TREATMENT WITH A GLP-1 AGONIST OR DPP-4 INHIBITOR ALSO APPEARS TO IMPROVE INSULIN RESISTANCE AND SENSITIVITY.34,41,42,45 A 52-WEEK TRIAL FOUND A SIGNIFICANT REDUCTION IN INSULIN RESISTANCE WITH LIRAGLUTIDE 1.2 mg OR 1.8 mg ONCE DAILY (–0.65% AND –1.35%, RESPECTIVELY) COMPARED WITH A 0.85% INCREASE WITH GLIMEPIRIDE (P=.0249 AND P=.0011 VS LIRAGLUTIDE 1.2 mg AND 1.8 mg, RESPECTIVELY).45 ANOTHER TRIAL FOUND COMPARABLE IMPROVEMENT IN INSULIN SENSITIVITY FOLLOWING 52 WEEKS OF TREATMENT WITH EXENATIDE OR INSULIN GLARGINE (0.9 VS 1.1 mg/min·1/kg·1, RESPECTIVELY; P=.49).34

These preclinical and clinical data regarding pancreatic β-cell function must be viewed as preliminary, and require further investigation. If confirmed, the ability to alter the natural progression of β-cell loss in T2DM and/or to reduce insulin resistance would be of significant clinical value.

Incretin effects on other causes of T2DM
Both the GLP-1 agonists and the DPP-4 inhibitors affect other mechanisms involved in the pathogenesis of T2DM. Several trials have shown a significant reduction in fasting glucagon secretion with GLP-1 agonist37 or DPP-4 inhibitor treatment.33,46,47 THE ADDITION OF EXENATIDE OR LIRAGLUTIDE TO METFORMIN, A SUFONYLUREA, OR BOTH FOR 26 WEEKS RESULTED IN A REDUCTION IN FASTING GLUCAGON SECRETION OF 12.3 AND 19.4 NG/L, RESPECTIVELY (P=.1436), AFTER 26 WEEKS.37 ADDITION OF SAXAGLIPTIN TO A SUBMAXIMAL DOSE OF A SUFONYLUREA RESULTED IN A REDUCTION OF GLUCAGON SECRETION OF 0.8 NG/L COMPARED WITH AN INCREASE OF 4.5 NG/L WITH UPTITRATION OF THE SUFONYLUREA ALONE FOR 24 WEEKS. A 2-WEEK CROSSOVER TRIAL COMPARING EXENATIDE WITH SITAGLIPTIN SHOWED THAT COMPARED WITH SITAGLIPTIN, EXENATIDE REDUCED POSTPRANDIAL GLUCAGON BY 12% (P=.0011)47 (FIGURE 2); IN ADDITION, EXENATIDE SLOWED THE GASTRIC EMPTYING RATE BY 44% (P<.0001), WITH A COMMENSURATE DECREASE IN TOTAL CALORIC INTAKE OF 134 KCal WITH EXENATIDE VS AN INCREASE OF 130 KCal WITH SITAGLIPTIN (P=.0227).47

Summary
The multifactorial nature of the pathogenesis of T2DM provides an opportunity to combine treatments that act upon different mechanisms. In addition to improving insulin resistance and pancreatic β-cell dysfunction, the GLP-1 agonists and DPP-4 inhibitors improve the impaired incretin response, as well as increase insulin secretion and reduce glucagon secretion, both in a glucose-dependent manner. As a result of these multiple actions, the GLP-1 agonists and DPP-4 inhibitors lower both fasting and postprandial glucose levels. The effects of GLP-1 agonists tend to be greater, probably because they produce pharmacologic levels of GLP-1 compared to physiologic levels with the DPP-4 inhibitors. Another difference is that unlike the DPP-4 inhibitors, the GLP-1 agonists also slow gastric emptying and promote satiety.

References


Glucose-lowering effects of incretin-based therapies

R. Keith Campbell, PharmD, MBA, CDE; Michael E. Cobble, MD, FNLA; Timothy S. Reid, MD; Mansur E. Shomali, MD, CM

TAKE-HOME POINTS

• Glucagon-like peptide (GLP-1) agonists and dipeptidyl peptidase (DPP-4) inhibitors effectively lower blood glucose levels in a glucose-dependent manner, which results in a low incidence of hypoglycemia

• Reduction of glycosylated hemoglobin is greater with GLP-1 agonists (up to 1.5%) than with DPP-4 inhibitors (up to 0.9%), as is reduction of postprandial glucose (PPG)

• GLP-1 agonists and DPP-4 inhibitors vary in dosing (frequency, route of administration), contraindications, and requirement for dose adjustments with renal impairment

• GLP-1 agonists are emphasized in the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) 2009 guidelines and the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) 2009 consensus statement

Introduction

The selection of glucose-lowering therapies is dependent on many factors, including stage of disease progression, comorbidities, and previous treatments, as highlighted in the 3 cases. Other factors include an agent’s efficacy in lowering blood glucose levels, side effects and tolerability, safety, convenience and ease of use, and cost, as well as a patient’s current glycosylated hemoglobin (A1C) level. The mechanisms of action of concurrent glucose-lowering therapies also should be considered, since using therapies with complementary mechanisms is desirable. This article will focus on efficacy factors, while nonglycemic factors, including safety and tolerability, will be discussed in the next article in this supplement (“Safety, tolerability, and nonglycemic effects of incretin-based therapies”). Among these many factors, 2 concerning efficacy deserve discussion at this point.

First, the magnitude to which a pharmacologic option typically lowers blood glucose varies from 0.5% to 3.5% as either monotherapy or combination therapy (Figure 1). According to the AACE/ACE 2009 recommendations, monotherapy is appropriate if the initial A1C level is 6.5% to 7.5%, while dual therapy is appropriate if the A1C level is 7.6% to 9.0%. If the A1C level is >9.0%, however, combination (dual or triple) therapy is required. In contrast, the ADA/EASD 2009 consensus statement provides more general options. These treatment recommendations are based on landmark trials that show the risk of microvascular and, perhaps, macrovascular complications are decreased substantially.

The second factor to consider is the effectiveness of each agent in lowering both fasting plasma glucose (FPG) and PPG. As demonstrated by Monnier et al, at an A1C level of approximately 8% to 8.5%, FPG and PPG contribute equally to the A1C level. At A1C >8.5%, the contribution of FPG increases and PPG decreases. Conversely, at A1C <8%, the contribution of PPG increases and FPG decreases. Thus, the increasing predominance of PPG as patients gain better glycemic control suggests that an agent that effectively lowers both FPG and PPG is needed to achieve the target glycemic goal of ≤7%.

The correlation between PPG and cardiovascular risk is also worth mentioning here. A number of studies have linked elevated PPG levels to increased cardiovascular risk, and 2 studies have shown PPG to be more predictive than FPG for cardiovascular risk. One recent study, NAVIGATOR, sought to explore this connection further but could not provide definitive results. While the study found that 5 years of nateglinide provided no protection against progression of cardiovascular disease in patients with impaired glucose toler-
Distinguishing among incretin-based therapies

Supplement to The Journal of Family Practice  |  Vol 59, No 9, Suppl 1  |  September 2010

 ance and cardiovascular disease (or risk factors), it also revealed a paradoxical increase in PPG levels in patients taking the drug. Research on this issue will no doubt continue. The agents that provide the greatest reduction in PPG are insulin, GLP-1 agonists, and pramlintide.4 Of course, benefits of glycemic control must be weighed against potential adverse effects of each agent, as will be discussed in the next article.

Selecting initial therapy

Metformin, in combination with lifestyle intervention, has become the recommended first-line pharmacologic agent for the treatment of type 2 diabetes mellitus (T2DM), unless there is a contraindication, such as renal disease, hepatic disease, heart failure, gastrointestinal intolerance, or risk of lactic acidosis. This is because of its efficacy, safety, absence of weight gain, and relatively low cost.1,4 But how should therapy be modified if metformin is no longer effective in maintaining glycemic control or if it is contraindicated? Let’s return to our 3 cases and focus on the glycemic effects of the glucose-lowering agents. (The next article focuses on nonglycemic effects.) As a reminder, in these cases we address dual oral therapy failure, intolerance to metformin monotherapy, and metformin failure.

Modifying therapy

As we focus our attention on the GLP-1 agonists (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin, saxagliptin), we will keep in mind the current indications and limitations of use, as approved by the US Food and Drug Administration (FDA) (TABLE 1).15-19 We also need to keep in mind the increasing role of the GLP-1 agonists and DPP-4 inhibitors in the treatment of patients with T2DM, as reflected in the ADA/EASD 2009 consensus guidelines1 and especially the 2009 consensus statement by the AACE/ACE (FIGURE 2).4 Finally, as described in the 2010 Standards of Medical Care in Diabetes by the ADA, in reflection of recent clinical trials such as ACCORD, ADVANCE, and VADT, the target glycemic goal must be carefully determined based on many factors, including patient comorbidity, duration of T2DM, life expectancy, and history of hypoglycemia.30

Case 1

This 53-year-old man was recently diagnosed with T2DM, with a baseline A1C of 7.5%. He is intolerant of metformin and wants to be treated with an alternative medication. In the case of metformin intolerance or a contraindication to metformin, a thiazolidinedione, DPP-4 inhibitor, GLP-1 agonist, or α-glucosidase inhibitor is recommended by the AACE/ACE if the patient’s A1C level is 6.5% to 7.5% (FIGURE 2).4,5 The safety and tolerability associated with each treatment option, such as hypoglycemia and weight gain, should be discussed with the patient.

GLP-1 agonists and DPP-4 inhibitors as monotherapy

Use of GLP-1 agonists and DPP-4 inhibitors as monotherapy in combination with lifestyle intervention has been investigated in several clinical trials.2,3,21-25 Generally, as monotherapy, DPP-4 inhibitors have been shown to reduce A1C by 0.5% to 0.9% and GLP-1 agonists by 0.5% to 1.5%.1,3 Increasing the dose provides additional modest glucose reduction. For our patient in Case 1, therefore, either of the DPP-4 inhibitors, sitagliptin or saxagliptin, would be expected to reduce his A1C from his current level of 7.5% to the target level of <7.0%. The GLP-1 agonists, exenatide or liraglutide, would also be expected to reduce his A1C to the target level.

FIGURE 1  Range of A1C lowering by class of glucose-lowering agent as monotherapy or by lifestyle modification1-3

<table>
<thead>
<tr>
<th>Class</th>
<th>Range of A1C (%) reduction as monotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPP-4 I</td>
<td>1-2</td>
</tr>
<tr>
<td>Glimepiride (Glinide)</td>
<td>1-1.5</td>
</tr>
<tr>
<td>AGI</td>
<td>1-1.5</td>
</tr>
<tr>
<td>GLP-1 A</td>
<td>1-1.5</td>
</tr>
<tr>
<td>Thiazolidinedione</td>
<td>1-1.5</td>
</tr>
<tr>
<td>Sulfonylurea</td>
<td>1-1.5</td>
</tr>
<tr>
<td>Insulin</td>
<td>1-1.5</td>
</tr>
<tr>
<td>Metformin</td>
<td>1-1.5</td>
</tr>
<tr>
<td>Lifestyle</td>
<td>1-1.5</td>
</tr>
</tbody>
</table>

AGI, α-glucosidase inhibitor; DPP-4 I, dipeptidyl peptidase-4 inhibitor; GLP-1 A, glucagon-like peptide-1 agonist.

aAdapted to include sitagliptin and saxagliptin.
bAdapted to include exenatide and liraglutide.
Results of clinical trials have shown that monotherapy with a DPP-4 inhibitor or GLP-1 agonist reduces FPG levels by 11 to 22 mg/dL and 11 to 61 mg/dL, respectively. Reductions in PPG levels range from 24 to 35 mg/dL for the DPP-4 inhibitors and 21 to 48 mg/dL for the GLP-1 agonists. The substantial reduction in PPG is especially important as the A1C level drops to <8.0% and approaches the target level of <7.0%, as is the case with this patient.

The greater reductions in FPG and PPG observed with GLP-1 agonists compared with DPP-4 inhibitors likely stem from the pharmacologic level of GLP-1 activity achieved with the GLP-1 agonists and their direct action on the GLP-1 receptor, which is in contrast to the indirect action of the DPP-4 inhibitors and the resulting lower physiologic levels of endogenous GLP-1.

The glucose-lowering ability of DPP-4 inhibitors and GLP-1 agonists appears to be affected by the baseline A1C level and history of previous treatment. A monotherapy trial with sitagliptin showed that patients with a baseline A1C level ≥9.0% experienced a reduction in A1C of 1.5% compared with 0.6% for those with a baseline A1C level <8.0%. For the patient in Case 1, the reduction of 0.6% would be sufficient to lower his A1C to <7.0%.

Similarly, limited data suggest that patients previously treated with glucose-lowering therapy achieve a smaller reduction in A1C compared with those managed with diet and exercise alone. In a study by Garber et al, patients previously managed with diet and exercise alone achieved a reduction in A1C of 1.2% and 1.6% with liraglutide 1.2 mg and 1.8 mg once daily, respectively, vs 0.5% and 0.7% for those previously treated with glucose-lowering monotherapy.

In summary, data from clinical trials support the efficacy of DPP-4 inhibitors and GLP-1 agonists as monotherapy in combination with lifestyle intervention. In the case of this 53-year-old man with an A1C level of 7.5%, either of the 2 DPP-4 inhibitors or the 2 GLP-1 agonists would provide sufficient glucose-lowering to achieve the target A1C.
### FIGURE 2 An algorithm for glycemic control by the AACE/ACE*4,5

#### LIFESTYLE MODIFICATION

- **A1C 6.5–7.5%**
  - **Monotherapy**
    - **CASE 1**
      - MET
      - DPP4
      - GLP-1
      - TZD
      - AGI
    - 2–3 Mos.***
  - **Dual Therapy**
    - **MET +**
      - GLP-1 or DPP4
      - TZD
      - Glinide or SU
    - **TZD +**
      - GLP-1 or DPP4
    - **MET +**
      - Colesevelam
      - AGI
    - 2–3 Mos.***
  - **Triple Therapy**
    - **MET + GLP-1 or DPP4 +**
      - TZD
      - Glinide or SU
    - 2–3 Mos.***
  - **INSULIN ± Other Agent(s)**

- **A1C 7.6–9.0%**
  - **Dual Therapy**
    - **CASE 2**
      - MET +
        - GLP-1 or DPP4
        - TZD
        - SU or glinide
    - 2–3 Mos.***
  - **Triple Therapy**
    - **CASE 3**
      - MET +
        - GLP-1 or DPP4
      - TZD
      - GLP-1 or DPP4
      - SU
    - 2–3 Mos.***
  - **INSULIN ± Other Agent(s)**

<table>
<thead>
<tr>
<th>A1C, glycosylated hemoglobin; AGI, α-glucosidase inhibitor; DPP4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; MET, metformin; SU, sulfonylurea; TZD, thiazolidinedione.</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>To achieve A1C goal ≤6.5%, which may not be appropriate for all patients.</em>*</td>
</tr>
<tr>
<td><strong>For patients with diabetes and A1C &lt;6.5%, pharmacologic Rx may be considered.</strong>*</td>
</tr>
<tr>
<td>***If A1C goal not achieved safely.</td>
</tr>
<tr>
<td>†Preferred initial agent.</td>
</tr>
<tr>
<td>1DPP-4 if HbA1c and FPG or GLP-1 if HbA1c.</td>
</tr>
<tr>
<td>2TZD if metabolic syndrome and/or nonalcoholic fatty liver disease (NAFLD).</td>
</tr>
<tr>
<td>3AGI if HbA1c.</td>
</tr>
<tr>
<td>4Glinide if HbA1c or SU if HbA1c.</td>
</tr>
<tr>
<td>5Low-dose secretagogue recommended.</td>
</tr>
<tr>
<td>6(a) Discontinue insulin secretagogue with multidose insulin; b) Can use pramlintide with prandial insulin.</td>
</tr>
<tr>
<td>7Decrease secretagogue by 50% when added to GLP-1 or DPP-4.</td>
</tr>
<tr>
<td>8If A1C &lt;8.5%, combination Rx with agents that cause hypoglycemia should be used with caution.</td>
</tr>
<tr>
<td>9If A1C &gt;8.5%, in patients on dual therapy, insulin should be considered.</td>
</tr>
</tbody>
</table>

level of <7.0%. Furthermore, although a greater reduction has been observed with GLP-1 agonists (0.5% to 1.5%), the DPP-4 inhibitors also should provide for significant reduction (0.5% to 0.9%) of this patient’s PPG level.

We now turn our attention to the glycemic effects of the GLP-1 agonists and DPP-4 inhibitors in combination with 1 or more pharmacologic agents.

Case 2
This 47-year-old man was diagnosed with T2DM 2.5 years ago. The addition of pioglitazone to the combination of lifestyle intervention and metformin has resulted in significant edema and weight gain. He refuses to take a diuretic because of previous experience and wants to discontinue his pioglitazone. He currently has an A1C of 7.0%. What should replace pioglitazone for this patient, who is no longer achieving glycemic control with lifestyle intervention and metformin?

For a patient with an A1C level of 7.6% to 9.0%, the AACE/ACE 2009 guidelines suggest adding a GLP-1 agonist, DPP-4 inhibitor, or thiazolidinedione (FIGURE 2). Among these 3 options, GLP-1 agonists and DPP-4 inhibitors are preferred due to both their efficacy data when combined with metformin and their overall safety profiles. The GLP-1 agonists are preferred over the DPP-4 inhibitors due to better reduction of PPG levels and potential for substantial weight loss. Thiazolidinediones would be the third choice because of their risks of weight gain, edema, congestive heart failure, and fractures.

GLP-1 agonists and DPP-4 inhibitors in combination with metformin
Many clinical trials have been conducted with GLP-1 agonists and DPP-4 inhibitors in combination with lifestyle intervention and metformin (TABLE 2). These trials generally show similar trends in A1C reduction as with monotherapy, although a somewhat greater reduction has been seen with GLP-1 agonists compared with DPP-4 inhibitors. Increasing the dose may provide additional modest glucose reduction. As is typical with monotherapy, patients with a higher baseline A1C level (ie, ≥9.0%) achieve greater A1C reduction. The same holds true for reductions in FPG and PPG levels. For the patient in Case 2, who had an A1C level of 7.8% prior to addition of pioglitazone, discontinuation of pioglitazone and addition of either exenatide or liraglutide to lifestyle intervention and metformin would be expected to lower his A1C level to the target of <7.0%. Although possible, it is unlikely that addition of sitagliptin or saxagliptin would achieve the target A1C level.

Choosing among incretin-based therapies
The choice of 1 GLP-1 agonist or DPP-4 inhibitor over another can be difficult, but recent data from 3 clinical trials provide some guidance in terms of efficacy and safety. Each of these trials has been a direct comparison of add-on therapy with 2 incretin-based therapies. The first, by Buse et al, was an open-label comparison of exenatide 10 µg twice daily with liraglutide 1.8 mg once daily for 26 weeks. Patients with inadequately controlled T2DM on maximally tolerated doses of metformin, sulfonylurea, or both participated in the study (N=464). The mean change in A1C level from baseline to Week 26 was significantly greater with liraglutide than with exenatide (+1.1% vs +0.8%, respectively; P<.0001) (FIGURE 3A). The difference between the 2 groups was greatest for patients with a baseline A1C ≥10% (liraglutide, −2.4%; exenatide, −1.2%). Furthermore, more patients in the liraglutide group than in the exenatide group achieved an A1C level <7% (54% vs 43%; P=.0015). This may have been a result of a significantly greater reduction in FPG with liraglutide than with exenatide (29 vs 11 mg/dL; P<.0001). The reduction in PPG after breakfast and after dinner (but not after lunch) from baseline to Week 26, however, was significantly greater with exenatide than with liraglutide (FIGURE 3B). Liraglutide increased mean fasting insulin secretion (+12.4 pmol/L), whereas there was a small reduction with exenatide (−1.4 pmol/L; P=.0355). Fasting glucagon secretion was reduced in both the liraglutide and exenatide groups, but the difference was not significant (−19.4 vs −12.3 ng/L; P=.1436). A 14-week extension of this study showed that patients who were switched from exenatide to liraglutide experienced a significant further reduction in A1C (−0.3%), FPG (−16 mg/dL), and body weight (−0.9 kg) (P<.0001 for all mean values). In those who continued liraglutide, A1C (−0.1%) and FPG (−4 mg/dL) levels remained relatively stable, while body weight was further reduced (−0.4 kg) (P<.009).

The second study was a crossover trial by DeFronzo et al that compared exenatide with sitagliptin in patients inadequately controlled with metformin (N=95). In addition to maintaining a stable dose of metformin, patients received either exenatide 5 µg twice daily for 1 week followed by 10 µg twice daily for 1 week, or sitagliptin 100 mg every morning for 2 weeks. Patients were then crossed over to the other treatment. While the mean change from baseline FPG (178 mg/dL) was similar in
the exenatide and sitagliptin groups (−15 vs −19 mg/dL; *P*=.3234), the change from baseline 2-hour PPG (245 mg/dL) was −112 mg/dL for exenatide vs −37 mg/dL for sitagliptin (*P*<.0001). Following crossover, the patients who were switched from exenatide to sitagliptin experienced an increase in PPG of approximately 73 mg/dL (from 133 to 205 mg/dL), whereas those switched from sitagliptin to exenatide experienced a further reduction of −76 mg/dL (from 209 to 133 mg/dL). Consistent with these observations, exenatide was more effective than sitagliptin in augmenting postprandial insulin secretion and suppressing postprandial glucagon secretion. Exenatide, but not sitagliptin, significantly slowed gastric emptying (*P*<.0001).

In the third trial, Pratley et al compared the addition of liraglutide 1.2 mg or 1.8 mg and sitagliptin 100 mg once daily in patients inadequately controlled with metformin 1500 mg daily or more (*N*=665). From a mean A1C level of 8.5% at baseline, reductions in A1C after 26 weeks were 1.2% for liraglutide 1.2 mg and 1.5% for liraglutide 1.8 mg vs 0.9% for sitagliptin (*P*<.0001 for both liraglutide doses). Mean reductions in FPG were 34 mg/dL for liraglutide 1.2 mg and 39 mg/dL for liraglutide 1.8 mg vs 15 mg/dL for sitagliptin. Weight decreased in all 3 groups but by significantly more
with liraglutide: 2.9 kg with liraglutide 1.2 mg and 3.4 kg with liraglutide 1.8 mg vs 1.0 kg with sitagliptin ($P<.0001$ for both liraglutide doses). Both liraglutide doses resulted in significant improvements from base-line in homeostasis model assessment of $\beta$-cell function (HOMA-B): 27.23% with liraglutide 1.2 mg and 28.70% with liraglutide 1.8 mg vs 4.18% with sitagliptin ($P<.0001$ for both liraglutide doses), whereas no treatment differences were observed for HOMA–insulin resistance or fasting insulin concentration.

The results of these trials indicate that for this 47-year-old man, a GLP-1 agonist would be a better choice to replace pioglitazone, primarily because the A1C reduction of $\geq 1.0\%$ that can be achieved with this class of drug, and which is needed in this case, is greater than the reduction that can be expected with a DPP-4 inhibitor. Other issues such as weight loss and low individual incidence of hypoglycemia, which also need to be considered, are discussed in the next article.

Case 3

This 68-year-old woman was diagnosed with T2DM 5 years ago. She has experienced disease progression with a rising A1C level despite dual oral therapy. Her current A1C is 7.4%. She also has peripheral arterial disease and osteoporosis, both of which are being treated. For a patient who has failed dual oral therapy with metformin and another agent, the AACE/ACE guidelines suggest the addition of a DPP-4 inhibitor, GLP-1 agonist, or thiazolidinedione (FIGURE 2).4,5 If a DPP-4 inhibitor or GLP-1 agonist is added, the dose of the sulfonylurea should be decreased by 50% due to the increased risk of hypoglycemia.1 Her mild renal insufficiency is also a consideration.

GLP-1 agonists and DPP-4 inhibitors in combination with metformin and other oral agents

Many clinical trials have been conducted with a GLP-1 agonist or DPP-4 inhibitor in combination with lifestyle intervention, metformin, and 1 or 2 other agents. As shown in TABLE 3, the reductions in A1C observed when a GLP-1 agonist or DPP-4 inhibitor is added to dual therapy are generally similar to those observed with GLP-1 agonist or DPP-4 inhibitor monotherapy, although reductions of up to 1.5% have been observed with the addition of liraglutide.46,47 Similarly, reductions in FPG with combination...
therapy—7 to 74 mg/dL with GLP-1 agonists and 14 to 29 mg/dL with DPP-4 inhibitors—have been comparable to those observed with monotherapy. These results provide evidence of the effectiveness of GLP-1 agonists and DPP-4 inhibitors in further lowering blood glucose levels when added to dual therapy in patients with advanced disease.

GLP-1 agonist and DPP-4 inhibitor trials compared with insulin

While sitagliptin is the only one of the 4 incretin-based therapies approved for use in combination with insulin (Table 1), several studies have compared the efficacy of adding exenatide, liraglutide, or sitagliptin with adding insulin glargine to other glucose-lowering therapy. These trials have generally shown a GLP-1 agonist to provide glucose-lowering ability comparable to that with insulin glargine. For example, separate 26-week trials compared exenatide and liraglutide with insulin glargine in patients suboptimally controlled with metformin and a sulfonylurea. In the first (N=551), both exenatide and insulin glargine decreased the mean A1C level 1.1%. The FPG level decreased 26 mg/dL in the exenatide group and 52 mg/dL in the insulin glargine group (P<.001). On the other hand, exenatide reduced PPG excursions compared with insulin glargine. In the second trial (N=576), the A1C level decreased 1.3% in the liraglutide group vs 1.1% in the insulin glargine group (P=.0015) and 0.2% in the placebo group (both, P<.0001 vs placebo). The FPG level decreased 28 and 32 mg/dL, respectively, in the liraglutide and insulin glargine groups and increased 10 mg/dL in the placebo group. Postprandial glucose decreased 33 and 29 mg/dL, respectively, in the liraglutide and glargine groups but did not change in the placebo group (P<.0001 vs liraglutide vs placebo). These trials showed that addition of exenatide or liraglutide to metformin and a sulfonylurea provides comparable glucose reduction to addition of insulin glargine.

GLP-1 agonists and DPP-4 inhibitors in combination with agents other than metformin

While metformin is the cornerstone of glucose-lowering therapy, GLP-1 agonists and DPP-4 inhibitors have been investigated as dual therapy in combination with agents other than metformin. The addition of liraglutide 0.6 mg, 1.2 mg, or 1.8 mg; rosiglitazone 4 mg; or placebo to glimepiride 2 mg to 4 mg was compared in patients with inadequately controlled blood glucose on monotherapy or combination therapy, excluding insulin (N=1041). After 26 weeks, the mean A1C level decreased 1.1% with either liraglutide 1.2 mg or 1.8 mg once daily and 0.4% with rosiglitazone 4 mg daily but increased 0.2% with placebo (all, P<.0001). Similarly, the decrease in FPG was significantly greater with liraglutide 1.2 mg and 1.8 mg compared with placebo (treatment difference, 47 mg/dL; P<.0001) and rosiglitazone 4 mg (treatment difference, 13 mg/dL; P<.001). Reductions in PPG were also significantly greater with liraglutide 1.2 mg and 1.8 mg (45 and 49 mg/dL, respectively) than with rosiglitazone 4 mg (32 mg/dL; P=.043 vs liraglutide 1.2 mg; P=.0022 vs liraglutide 1.8 mg) and placebo (7 mg/dL; P<.0001 for both liraglutide doses).

Two trials have investigated treatment with a DPP-4 inhibitor in combination with a thiazolidinedione. In 1 trial, patients (N=353) were randomized to receive saxagliptin 100 mg once daily or placebo in combination with pioglitazone 30 mg to 45 mg daily. After 24 weeks, the mean A1C level decreased 0.9% with the addition of sitagliptin and 0.2% with placebo (P<.001). The FPG level decreased 17 mg/dL in the sitagliptin group and increased 1 mg/dL in the placebo group (P<.001). Similar changes in A1C and FPG levels were observed in another trial involving the addition of saxagliptin 2.5 mg or 5 mg once daily to pioglitazone 30 mg to 45 mg or rosiglitazone 4 mg to 8 mg once daily. Reduction in the PPG area under the curve was greater with either dose of saxagliptin than with placebo.

The addition of saxagliptin to a submaximal dose of glyburide was compared with uptitration of glyburide in 768 patients with T2DM. Patients were randomized to receive saxagliptin 2.5 mg or 5 mg once daily in combination with glyburide 7.5 mg once daily, or glyburide 10 mg to 15 mg once daily for 24 weeks. The mean A1C level decreased 0.5% and 0.6% in the saxagliptin 2.5 mg and 5 mg groups, respectively, and increased 0.1% in the glyburide uptitration group (P<.0001 vs both saxagliptin groups). The FPG level decreased 7 and 10 mg/dL in the saxagliptin 2.5 mg and 5 mg groups, respectively, and increased 1 mg/dL in the glyburide uptitration group (P=.0218 and P=.002, respectively). Similar changes were observed in PPG (P<.0001).

These trials demonstrate that the efficacy of GLP-1 agonists and DPP-4 inhibitors extend to combined use with agents other than metformin.
Distinguishing among incretin-based therapies

Summary

Extensive experience from randomized clinical trials demonstrates the efficacy of GLP-1 agonists and DPP-4 inhibitors as monotherapy and in combination with metformin and other agents, although reductions in FPG and PPG, and consequently A1C, are greater with GLP-1 agonists than with DPP-4 inhibitors. This difference may result from the pharmacologic levels of GLP-1 activity that are achieved with the GLP-1 agonists and their direct action on the GLP-1 receptor. The GLP-1 agonists have attributes that would make either of them an appropriate choice in the management of all 3 patients in our case studies, while either DPP-4 inhibitor would be an appropriate choice for Case 1. Differences in dosing, administration, safety, and tolerability should be considered.

Table 3: Selected clinical trials of incretin-based therapies added to combination therapy

<table>
<thead>
<tr>
<th>Agent/clinical trial</th>
<th>Combination/duration (wk)</th>
<th>A1C (%)</th>
<th>% Patients achieving A1C &lt;7%</th>
<th>FPG (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Baseline</td>
<td>Change</td>
<td>Baseline</td>
</tr>
<tr>
<td>Exenatide (E)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kendall, 200541</td>
<td>Met + SU/30</td>
<td>8.5</td>
<td>-0.6</td>
<td>27</td>
</tr>
<tr>
<td>E, 5 µg BID</td>
<td></td>
<td>8.5</td>
<td>-0.6</td>
<td>34</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td>8.5</td>
<td>+0.2</td>
<td>9</td>
</tr>
<tr>
<td>Blonde, 200642</td>
<td>Met + SU/52</td>
<td>8.3</td>
<td>-1.1</td>
<td>48</td>
</tr>
<tr>
<td>E, 5 µg BID</td>
<td></td>
<td>8.3</td>
<td>-1.1</td>
<td>48</td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nauck, 200743</td>
<td>Met + SU/52</td>
<td>8.6</td>
<td>-1.0</td>
<td>32</td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td>8.6</td>
<td>-0.9</td>
<td>24</td>
</tr>
<tr>
<td>Aspart 70/30 BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heine, 200544</td>
<td>Met + SU/26</td>
<td>8.2</td>
<td>-1.1</td>
<td>46</td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td>8.3</td>
<td>-1.1</td>
<td>48</td>
</tr>
<tr>
<td>Glargine OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinman, 200745</td>
<td>TZD ± Met/16</td>
<td>7.9</td>
<td>-0.9</td>
<td>62</td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td>7.9</td>
<td>+0.1</td>
<td>16</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide (L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Russell-Jones, 200946</td>
<td>Met + Glim/26</td>
<td>8.3</td>
<td>-1.3</td>
<td>NR</td>
</tr>
<tr>
<td>L, 1.8 mg OD</td>
<td></td>
<td>8.2</td>
<td>-1.1</td>
<td>NR</td>
</tr>
<tr>
<td>Glargine</td>
<td></td>
<td>8.3</td>
<td>-0.2</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinman, 200947</td>
<td>Met + Rosi/26</td>
<td>8.5</td>
<td>-1.5</td>
<td>58</td>
</tr>
<tr>
<td>L, 1.2 mg OD</td>
<td></td>
<td>8.6</td>
<td>-1.5</td>
<td>54</td>
</tr>
<tr>
<td>L, 1.8 mg OD</td>
<td></td>
<td>8.4</td>
<td>-0.5</td>
<td>28</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sitagliptin (Si)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hermansen, 200748</td>
<td>Glim ± Met/24</td>
<td>8.3</td>
<td>-0.5</td>
<td>17</td>
</tr>
<tr>
<td>Si, 100 mg OD</td>
<td></td>
<td>8.3</td>
<td>+0.3</td>
<td>5</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A1C, glycosylated hemoglobin; BID, twice daily; FPG, fasting plasma glucose; Glim, glimepiride; Met, metformin; NR, not reported; OD, once daily; Rosi, rosiglitazone; SU, sulfonylurea; TZD, thiazolidinedione.

References


Safety, tolerability, and nonglycemic effects of incretin-based therapies

R. Keith Campbell, PharmD, MBA, CDE; Michael E. Cobble, MD, FNLA; Timothy S. Reid, MD; Mansur E. Shomali, MD, CM

Introduction
The GLP-1 agonists and DPP-4 inhibitors have important benefits beyond lowering glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose. Although an important treatment goal for type 2 diabetes mellitus (T2DM) is to reduce the risk of other diabetes-related diseases, eg, cardiovascular disease, many glucose-lowering agents cause weight gain, thereby adding to the burgeoning problem of obesity and related long-term consequences, as shown in our 3 case studies. In addition, cardiovascular risks associated with thiazolidinediones have become a major concern.

Side effects and their impact on patient tolerability are also important considerations when selecting and titrating therapy. Concerns about hypoglycemia can affect patient adherence to a medication regimen and a patient’s willingness to continue and intensify therapy, especially with insulin and sulfonylureas.1-3 As seen in Cases 1 (metformin-related diarrhea) and 2 (pioglitazone-related edema), patient adherence and willingness to continue therapy can be jeopardized by medication-related side effects.

Given these issues, the use of glucose-lowering medications that reduce related risk factors and have a favorable safety profile is advantageous. The GLP-1 agonists and DPP-4 inhibitors are desirable options, based on these considerations.

Reducing risk
The importance of weight
It is well recognized that weight gain is a major risk factor for T2DM and other disorders. It is also clear that concerns about weight gain adversely affect a patient’s willingness to begin treatment with glucose-lowering medications such as thiazolidinediones (TZDs), insulin, and sulfonylureas.1-3 The other side of the story is probably less appreciated—that is, weight loss can be a significant motivating factor for patients with T2DM that, in our experience, can improve adherence to lifestyle intervention and a medication regimen. In fact, improved quality of life, as assessed by physical and emotional domains, has been reported as a result of liraglutide-associated weight loss.4 In addition, multidimensional assessment of patient satisfaction generally has shown similar improvement with liraglutide 1.2 mg once daily and sitagliptin 100 mg once daily, and significantly greater improvement with liraglutide 1.8 mg once daily.5 Consequently, the ability of GLP-1 agonists to promote weight loss in most patients and of DPP-4 inhibitors to be weight neutral offers important benefits. Weight is an

TAKE-HOME POINTS

• The glucagon-like peptide (GLP)-1 agonists promote a 1 kg to 4 kg weight loss and satiety, while the dipeptidyl peptidase (DPP)-4 inhibitors are usually weight neutral
• The GLP-1 agonists and DPP-4 inhibitors have a favorable safety profile, including rare occurrence of severe hypoglycemia and a low incidence of mild to moderate hypoglycemia
• Mild to moderate nausea associated with GLP-1 agonists generally resolves over 4 to 8 weeks and can be minimized by dose escalation strategies
• Hypersensitivity reactions occur infrequently with DPP-4 inhibitors
• Active surveillance and investigation are ongoing regarding the possible association of GLP-1 agonists and/or DPP-4 inhibitors with acute pancreatitis; thyroid medullary cancer; and with cardiovascular disease

The authors received editorial assistance from the Primary Care Education Consortium and WriteHealth, LLC in the development of this activity and honoraria from the Primary Care Education Consortium. They have disclosed that Dr Campbell is on the advisory board for Daiichi-Sankyo and the speakers bureau for Eli Lilly and Co; Dr Cobble is on the advisory board for Abbott Laboratories, AstraZeneca, and Eli Lilly and Co and speakers bureau for Abbott Laboratories, AstraZeneca/Bristol Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, and Novo Nordisk Inc; Dr Reid is on the advisory board and speakers bureau for Amylin Pharmaceuticals, Medtronic, Novo Nordisk Inc, and sanofi-aventis; and Dr Shomali is on the advisory board for Novo Nordisk Inc and speakers bureau for Amylin Pharmaceuticals, Eli Lilly and Co, sanofi-aventis, and Takeda Pharmaceuticals.
issue in all 3 of our patient cases, especially in Cases 1 and 2, where the patients’ body mass indices (BMIs) are ≥30 kg/m².

Either as monotherapy or when added to glucose-lowering therapy, twice-daily exenatide or once-daily liraglutide generally promotes a 1 kg to 4 kg weight loss.4,6-11 The addition of exenatide or liraglutide to metformin, a sulfonylurea, or both resulted in a mean 2.9 kg weight loss with exenatide and a 3.2 kg loss with liraglutide after 26 weeks.12 Patients who continued liraglutide for an additional 14 weeks lost an additional 0.4 kg, while patients switched from exenatide to liraglutide lost an additional 0.9 kg.13 The amount of weight lost is greater with a higher baseline BMI.14,15 It is important to note, however, that 16% of patients did not experience any weight loss,14 possibly because no specific caloric restriction was required.14,16 Slight increases to slight decreases in weight have been observed in clinical trials with sitagliptin and saxagliptin.17-23 Comparison of liraglutide with sitagliptin showed a mean weight loss of 2.9 kg and of endogenous GLP-1.25 This may explain the ability of GLP-1 agonists—but not DPP-4 inhibitors—to promote satiety and reduce caloric intake.26,27 In a cross-over comparison of exenatide with sitagliptin, caloric intake during a standardized meal decreased with exenatide (−134 kcal) and increased with sitagliptin (+130 kcal) (P=.0227).16

The possibility that the nausea associated with GLP-1 agonists but not DPP-4 inhibitors is the reason for the difference in weight effects has been investigated. Analyses have shown, however, that the weight loss observed with GLP-1 agonists is independent of nausea.4,10,28 For example, in a study by Garber et al,4 there was no difference in the amount of weight lost among patients who experienced liraglutide-associated nausea for >7 days, for 1 to 7 days, or not at all. The finding that nausea generally resolved within the first few weeks of liraglutide treatment, while weight loss was maintained over the 52 weeks of the trial, provides further evidence that nausea is not the cause of weight loss (FIGURE 1).4

![FIGURE 1](chart.png)

Similar long-term weight loss has been observed with exenatide: weight loss was achieved through 30 weeks (-3.0 kg; \(P=0.05\) vs baseline) of double-blind treatment and maintained during an additional 52 weeks of open-label treatment (-5.3 kg; \(P<0.05\) vs baseline). 29

**Cardiovascular benefits**

The effects of incretin therapy on markers of cardiovascular disease have been assessed in several clinical trials (Table 1). 3,4,8-12,17,22,30,31 In general, these trials demonstrate small but significant reductions in systolic blood pressure (1 to 7 mm Hg) with the GLP-1 agonists; diastolic blood pressure, however, is not significantly affected. 3,8-12,30,31 There are insufficient data regarding the DPP-4 inhibitors. 17,22

Effects on the lipid profile also have been investigated, 3,4,8-12,17,22,30,31 but differences among the agents are difficult to assess because of different baseline lipid levels and the limited number of direct comparative studies. In general, clinical studies show that low-density lipoprotein (LDL) cholesterol is reduced by 1 to 17 mg/dL with the GLP-1 agonists and increased by 3 to 9 mg/dL with the DPP-4 inhibitors. Changes in high-density lipoprotein (HDL) cholesterol are generally small for both GLP-1 agonists and DPP-4 inhibitors, ranging from an increase of 5 mg/dL to a decrease of 2 mg/dL. The greatest change in the lipid profile is in the triglyceride level, with a reduction of 12 to 40 mg/dL with the GLP-1 agonists, while the triglyceride changes observed with the DPP-4 inhibitors range from a reduction of 35 mg/dL to an increase of 16 mg/dL.

Two studies have directly compared the effects on the lipid profile of 2 incretin agents over 26 weeks. In the first study, exenatide and liraglutide showed similar changes in LDL cholesterol (-7 vs -8 mg/dL, respectively) and HDL cholesterol (-1 vs -1 mg/dL, respectively) levels, but liraglutide showed a significantly greater reduction in triglyceride levels than exenatide (-36 vs -20 mg/dL, respectively; \(P=0.0485\)). 12 The second study compared liraglutide 1.2 mg and 1.8 mg once daily and sitagliptin 100 mg once daily. 3 LDL cholesterol increased by 1 mg/dL in both liraglutide groups and by 2 mg/dL in the sitagliptin group, while there was no change in HDL cholesterol with either dose of liraglutide or sitagliptin. The triglyceride level decreased by 17 mg/dL in the liraglutide 1.2 mg group, 38 mg/dL in the liraglutide 1.8 mg group, and 35 mg/dL in the sitagliptin group. None of the differences between either liraglutide group and sitagliptin were statistically significant.

Effects on the lipid profile appear to be durable. Klonoff et al showed that the effects of exenatide on the lipid profile were sustained over 3.5 years of follow-up (in a 30-week randomized, double-blind trial followed by a 3-year open-label extension). 34 In patients younger than 65 years, changes from baseline were as follows: total cholesterol, -10 mg/dL (\(P=0.0056\)); LDL cholesterol, -11 mg/dL (\(P=0.0012\)); HDL cholesterol, +8 mg/dL (\(P=0.0001\)); and triglycerides, -44 mg/dL (\(P=0.0042\)). Similar changes were observed in those 65 years and older.

The cardiovascular benefits of incretin therapy may extend beyond blood pressure and the lipid profile. An exploratory subanalysis of a randomized controlled trial with liraglutide showed a significant decrease in plasminogen activator inhibitor-1, an inflammatory biomarker, and B-type natriuretic peptide, a marker of left ventricular dysfunction. 32 No significant effect on high-sensitivity C-reactive protein, interleukin-6, or tumor necrosis factor-\(\alpha\) was observed.

While not appropriate as primary therapy, the effect of the GLP-1 agonists on blood pressure and of the GLP-1 agonists and DPP-4 inhibitors on the lipid profile could be an added benefit for all patients with T2DM because of the strong association between T2DM and cardiovascular disease. This can be seen in all 3 of our cases: Case 1 (hypertriglyceridemia), Case 2 (essential hypertension), and Case 3 (peripheral arterial disease).

**Favorable safety profile**

**Overview**

In general, GLP-1 agonists and DPP-4 inhibitors are well tolerated. Because of concerns about hypoglycemia with glucose-lowering agents, signs and symptoms of hypoglycemia have been closely monitored in clinical trials. The low incidence and mild to moderate severity of hypoglycemia are important attributes of the GLP-1 agonists and DPP-4 inhibitors.

Other than hypoglycemia, the most common adverse reaction reported in ≥5% of patients and more commonly than with placebo are shown in Table 2. 33-36 Other medication-specific side effects are seen infrequently but bear mentioning. An increased international normalized ratio, sometimes with bleeding, has been noted with combined use of exenatide and warfarin. 33 Immune-related events (eg, urticaria) have been reported with exenatide 34 and have been observed to occur more frequently with liraglutide than with com-
TABLE 1  Selected studies with GLP-1 agonists and DPP-4 inhibitors assessing cardiovascular end points4,8-12,17,22,30,31

<table>
<thead>
<tr>
<th>Agent/clinical trial</th>
<th>Concomitant treatment; duration (wk)</th>
<th>Change from baseline</th>
<th>Systolic blood pressure (mm Hg)</th>
<th>LDL cholesterol (mg/dL)</th>
<th>HDL cholesterol (mg/dL)</th>
<th>Triglycerides (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exenatide (E)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moretto, 200830</td>
<td>Diet/exercise; 24</td>
<td></td>
<td>-4</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>E, 5 µg BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td></td>
<td>-4</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td>0</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Blonde, 2006a</td>
<td>MET + SU; 82 wk</td>
<td></td>
<td>-1</td>
<td>-2</td>
<td>+5</td>
<td>-39</td>
</tr>
<tr>
<td>E, 5 µg BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td></td>
<td>-1</td>
<td>-2</td>
<td>+5</td>
<td>-39</td>
</tr>
<tr>
<td>Nauck, 200731</td>
<td>MET + SU; 52 wk</td>
<td></td>
<td>-5</td>
<td>NC</td>
<td>NR</td>
<td>NC</td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premix aspart 70/30 BID</td>
<td></td>
<td></td>
<td>+1</td>
<td>NC</td>
<td>NR</td>
<td>NC</td>
</tr>
<tr>
<td>Zinman, 20079</td>
<td>TZD ± MET; 16 wk</td>
<td></td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liraglutide (L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garber, 20094</td>
<td>None; 52 wk</td>
<td></td>
<td>-2</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>L, 1.2 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L, 1.8 mg OD</td>
<td></td>
<td></td>
<td>-4</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Glimepiride, 8 mg OD</td>
<td></td>
<td></td>
<td>-1</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Russell-Jones, 200910</td>
<td>MET + GLIM; 26 wk</td>
<td></td>
<td>-4</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>L, 1.8 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin glargine</td>
<td></td>
<td></td>
<td>+1</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td>-1</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Zinman, 200911</td>
<td>MET + ROsi; 26 wk</td>
<td></td>
<td>-7</td>
<td>-11</td>
<td>-1</td>
<td>-34</td>
</tr>
<tr>
<td>L, 1.2 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L, 1.8 mg OD</td>
<td></td>
<td></td>
<td>-6</td>
<td>-9</td>
<td>-1</td>
<td>-29</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td>-1</td>
<td>-4</td>
<td>-1</td>
<td>-5</td>
</tr>
<tr>
<td>Buse, 200912</td>
<td>MET, SU, MET + SU; 26 wk</td>
<td></td>
<td>-3</td>
<td>-17</td>
<td>-2</td>
<td>-36</td>
</tr>
<tr>
<td>L, 1.8 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E, 10 µg BID</td>
<td></td>
<td></td>
<td>-2</td>
<td>-15</td>
<td>-2</td>
<td>-20</td>
</tr>
<tr>
<td>Sitagliptin (Si)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scott, 200717</td>
<td>Diet/exercise; 12 wk</td>
<td></td>
<td>NR</td>
<td>0</td>
<td>+1</td>
<td>-3</td>
</tr>
<tr>
<td>Si, 25 mg BID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Si, 50 mg BID4</td>
<td></td>
<td></td>
<td>NR</td>
<td>+1</td>
<td>+1</td>
<td>0</td>
</tr>
<tr>
<td>Glipizide, 5 mg OD</td>
<td></td>
<td></td>
<td>NR</td>
<td>0</td>
<td>0</td>
<td>+3</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td>NR</td>
<td>0</td>
<td>0</td>
<td>+16</td>
</tr>
<tr>
<td>Saxagliptin (Sa)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hollander, 200922</td>
<td>TZD; 24 wk</td>
<td></td>
<td>NR</td>
<td>+4</td>
<td>-1</td>
<td>-1</td>
</tr>
<tr>
<td>Sa, 2.5 mg OD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa, 5 mg OD</td>
<td></td>
<td></td>
<td>NR</td>
<td>+9</td>
<td>+2</td>
<td>-4</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td>NR</td>
<td>+3</td>
<td>0</td>
<td>-1</td>
</tr>
</tbody>
</table>

*Dose not included in currently approved prescribing information.

DPP, dipeptidyl peptidase; GLIM, glimepiride; GLP, glucagon-like peptide; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metformin; NC, no difference between baseline and study end; NR, not reported; OD, once daily; ROSI, rosiglitazone; SBP, systolic blood pressure; SU, sulfonylurea; TZD, thiazolidinedione.
Peripheral edema is more common when a thiazolidinedione is administered with saxagliptin than with placebo.36 While experience with GLP-1 agonists and DPP-4 inhibitors indicates that they have favorable safety profiles, some concerns have surfaced with 1 or more of these agents during clinical trials or from postmarketing reports. These include gastrointestinal side effects (principally nausea), acute pancreatitis, and hypersensitivity reactions. In addition, new standards recently adopted by the US Food and Drug Administration (FDA) are requiring further investigation of several issues for newly approved glucose-lowering drugs and those in development. These issues are discussed next.

**Hypoglycemia**

In contrast to other glucose-lowering drugs that stimulate insulin secretion, incretin-based therapies have a glucose-dependent mechanism of action that minimizes the risk of hypoglycemia. Preclinical investigation showed that GLP-1 acts on islet α-cells to strongly inhibit postprandial glucagon secretion.37,38 These observations were subsequently supported by early clinical investigations showing that administration of GLP-1 to healthy volunteers and people with T2DM augmented insulin secretion and decreased glucagon secretion in a glucose-dependent manner.39,40 Similar effects were also observed with a DPP-4 inhibitor.25 At the same time, GLP-1 has been shown not to suppress glucagon secretion at a plasma glucose level <65 mg/dL.41 This mechanism is believed to maintain the counterregulatory hormone response that serves to prevent hypoglycemia.

Accordingly, severe hypoglycemia has not been observed in monotherapy trials of exenatide,6,30 liraglutide,17,19 or saxagliptin.25 Mild to moderate hypoglycemia has been observed in 4% to 9% of patients treated with exenatide monotherapy6,30 and 0% to 12% of patients treated with liraglutide monotherapy17,19; by comparison, the incidence was 24% in patients treated with glimepiride monotherapy.4 Mild to moderate hypoglycemia has been found to be less frequent with sitagliptin and saxagliptin. In monotherapy and combination studies, 0% to 4% of patients treated with sitagliptin and 0% to 2% administered placebo experienced mild to moderate hypoglycemia.17,18,43-45 Mild to moderate hypoglycemia has not been observed in patients treated with saxagliptin monotherapy at doses of 2.5 mg to 40 mg.21 When saxagliptin was added to metformin, hypoglycemia was reported by 5.7% of patients compared with 5.0% of patients who added placebo to metformin.46 It is important to note that the incidence of mild to moderate hypoglycemia is increased in patients treated concomitantly with a GLP-1 agonist or DPP-4 inhibitor and a sulfonylurea. In 1 trial, 14% to 36% of patients treated with a combination of exenatide and a maximally effective dose of a sulfonylurea (glimepiride, glipizide, glyburide, chlorpropamide, tolazamide) reported mild to moderate hypoglycemia compared with 3% of those administered a placebo and a sulfonylurea.47 A trial involving the addition of saxagliptin to glyburide found that 13% to 15% of patients treated daily with glyburide 7.5 mg and saxagliptin 2.5 mg or 5 mg reported mild to moderate hypoglycemia compared with 10% of patients treated with glyburide 10 mg to 15 mg alone.23 For this reason, consideration should be given to reducing the dose of a sulfonylurea or secretagogue when combined with a GLP-1 agonist or DPP-4 inhibitor.31-35

Because of their low incidence of hypoglycemia, the American Diabetes Association/European Association for the Study of Diabetes panel recommends GLP-1 agonists for patients for whom hypoglycemia is particularly undesirable, such as those who perform manual
labor, drive a vehicle for a living, or operate heavy or
dangerous machinery. In fact, the US Federal Avia-
tion Administration lists the GLP-1 agonists and DPP-4
inhibitors as allowable medications for aviators. This
recommendation is particularly appropriate for the
building contractor in Case 1.

Nausea
Transient nausea is the most common GI side effect
associated with GLP-1 agonists, occurring in up to 57% of
patients treated with exenatide in clinical trials and
29% treated with liraglutide. Diarrhea and vomiting also
occurred, although rates were similar to rates with initiation of metformin. The high occurrence of transient nausea in these trials prompted investigators to implement a dose escalation strategy (see “Patient education and self-management” article in this supple-
ment). Since adoption of this strategy, a comparative trial of exenatide and liraglutide found that nausea occurred in 28% of patients treated with exenatide and in 26% treated with liraglutide. Nausea was generally transient, so that by Week 6 of therapy, 16% of patients treated with exenatide and 8% with liraglutide experienced nausea, and by Week 26, 9% of exenatide-treated patients and 3% of liraglutide-treated patients continued to experience nausea.

Of patients treated with the DPP-4 inhibitor sita-
gliptin, nausea has occurred in 1% to 2% compared with 1% of those receiving placebo. In patients treated with saxagliptin, nausea has occurred in 2% to 4% compared with 8% of those receiving placebo.

Acute pancreatitis
Acute pancreatitis has been observed in clinical trials and/or identified in postmarketing reports involving exenatide, liraglutide, and sitagliptin. Determining whether there is a true association of these agents with acute pancreatitis or this is just coincidental has been difficult, partly because patients with T2DM have a 2.8-fold greater risk of pancreatitis compared with nondiabetic subjects. A review of health insurance transactions with 1-year follow-up (June 2005 through June 2008) involving approximately 88,000 patients (exenatide, n=27,996; sitagliptin, n=16,276; approximately equal numbers of matched comparators) showed that the relative risk of pancreatitis was statistically the same with exenatide, sitagliptin, metformin, and glyburide.

In its ongoing review, the FDA has required the manufacturers of exenatide and sitagliptin to modify product labeling regarding the risk of acute pancreatitis and to conduct additional animal studies. As part of the January 2010 approval of liraglutide, the FDA required the manufacturer to perform mechanistic studies in animals and to conduct an epidemiologic evaluation using a large insurance claims database. In the interim, exenatide, liraglutide, and sitagliptin should be used cautiously if at all, in people with a history of pancreatitis. Furthermore, educating patients about the signs and symptoms of pancreatitis, including how to differentiate it from the transient nausea commonly observed with these agents, is critical. Patients at risk of developing acute pancreatitis (eg, due to excess alcohol consumption or gallstones) should not receive an incretin-based therapy. Therapy should be changed if a patient develops acute pancreatitis while using a GLP-1 agonist or DPP-4 inhibitor.

Hypersensitivity
Hypersensitivity reactions have been experienced by some patients treated with exenatide, liraglutide, sitagliptin, or saxagliptin. Postmarketing reports have described serious hypersensitivity reactions (anaphylaxis, angioedema) with exenatide. In clinical trials, 0.8% of patients treated with liraglutide and 0.4% treated with comparator agents experienced an immunogenic reaction, generally urticaria. With sitagliptin, anaphylaxis, angioedema, or exfoliative dermatitis, including Stevens-Johnson syndrome, typically occurs within 3 months but may occur after the first dose. Hypersen-
sitivity events, such as urticaria and facial edema, were shown to occur in 1.5% of patients treated with saxa-
agliptin 2.5 mg, 1.5% of those treated with saxagliptin 5 mg, and 0.4% of those receiving placebo. None of the events necessitated hospitalization or were life-threat-
ening. If a hypersensitivity reaction occurs, treatment should be discontinued.

Additional safety investigations
The FDA has required additional safety investigations for liraglutide, saxagliptin, and sitagliptin. These investiga-
tions will address observations made during preclini-
cal and clinical evaluation, as well as the new standards adopted by the agency in December 2008 regarding cardiovas-
cular safety for all new glucose-lowering agents.
Thyroid cancer

Rodent studies have suggested that liraglutide in doses many times those utilized in humans is associated with an increased risk of preneoplastic lesions that can lead to C-cell hyperplasia and medullary thyroid cancer, which occurs rarely in humans.52 Thyroid tumors have also been observed in rodents administered native GLP-134 or exenatide33 but not sitagliptin35 or saxagliptin.36 A slight increase in calcitonin, a marker for risk of medullary thyroid cancer.34 Liraglutide is also contraindicated in patients with a personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia syndrome type 2.34

Cardiovascular risk

The clinical evaluation of liraglutide and saxagliptin was completed prior to December 2008, when the FDA adopted the new cardiovascular safety standards for new antidiabetic drugs. Analyses of data from Phase 2 and 3 clinical trials indicate that liraglutide meets the new 2008 standard for ruling out an unacceptable increase in cardiovascular risk.52 While the overall rates of cardiovascular events were low in preapproval clinical trials, the more stringent criteria for postapproval evaluations were not met. Consequently, the FDA has required postapproval clinical trials of cardiovascular safety with liraglutide52 and saxagliptin.

Summary

The overall safety profiles of GLP-1 agonists and DPP-4 inhibitors are favorable, with a low incidence of hypoglycemia. This attribute, along with their weight and cardiovascular benefits, particularly with the GLP-1 agonists, make them appropriate choices in our 3 patient cases. Ongoing safety investigations with GLP-1 agonists and DPP-4 inhibitors will provide further clarity to the complete safety profiles of these agents.

References


51. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glipizide. Curr Med Res Opin. 2009;25:1019-1027.


Patient education and self-management

R. Keith Campbell, PharmD, MBA, CDE; Michael E. Cobble, MD, FNLA; Timothy S. Reid, MD; Mansur E. Shomali, MD, CM

Introduction
The comprehensive and long-term management of patients with type 2 diabetes mellitus (T2DM) requires that they assume primary responsibility for daily self-management. For this to occur, patient education is critical, yet it is time-consuming. Because our time as primary care physicians is limited, developing a diabetes care team, even informally, can be helpful in providing the comprehensive care that is needed. Beyond easing the amount of time we need to provide the patient education required, the patient is able to benefit from the specialized skills and knowledge of other team members, such as a nurse, pharmacist, dietitian, certified diabetes educator, or an exercise specialist. It is important, however, that as primary care physicians, we coordinate the care provided by the team so that treatment goals are clear, communication is maintained, and patient outcomes are optimal.

With this need for patient self-management supported by ongoing education in mind, let’s turn our attention to some issues of special importance with respect to the GLP-1 agonists and DPP-4 inhibitors.

Dosing and administration
There is considerable variability among the GLP-1 agonists and DPP-4 inhibitors with respect to their dosing and administration (TABLE). This variability enables you and your patients to select a treatment that best meets their needs.

Case 2
As you begin to talk about the GLP-1 agonists and DPP-4 inhibitors as treatment options for modifying his therapy, this 47-year-old office manager wants to know what side effects are likely and which, if any, might pose a problem at work.

You can begin by telling the patient that transient nausea has been a common occurrence in patients treated with a GLP-1 agonist and that a key factor regarding this side effect is how the medication is titrated (see accompanying article “Safety, tolerability, and nonglycemic effects of incretin-based therapies”). Exenatide and liraglutide should be administered using the dose escalation strategy outlined in the TABLE. You tell him that nausea is typically mild and usually peaks within 8 weeks of commencing treatment with exenatide6 and within 4 to 6 weeks with liraglutide.6,7 Should nausea persist and be troublesome, taking liraglutide with food has been helpful for some patients; otherwise, liraglutide can be taken at the same time each day irrespective of meals.2 You also note that saxagliptin and sitagliptin can be taken with or without food.3,4 While the prescribing information indicates that exenatide can...
be taken at any time within the 60-minute period before a meal, exenatide can be administered during but not after the meal if necessary to reduce nausea, without sacrificing its glucose-lowering effects; the satiety effect, however, may be blunted in some patients. Reduction in the postprandial glucose level has been shown to be greatest when exenatide is taken between 60 minutes before or by the end of the meal. Exenatide should not be taken after the meal, because transient low blood glucose levels may occur.

In patients with renal dysfunction, the dose of sitagliptin and saxagliptin but not liraglutide needs to be adjusted (TABLE). Exenatide should not be used in patients with a CrCl <30 mL/min or in ESRD; use with caution in patient with renal transplantation.

While his feelings are understandable, open communication with this patient can do much to allay his concerns. Although concerns about injecting outside the home are common with insulin, the need for this with a GLP-1 agonist is unlikely because of the twice-daily exenatide and once-daily liraglutide dosing schedules and the lack of need to intensely monitor blood glucose levels. However, if the patient eats breakfast at work or doesn’t eat breakfast at all, this may become an issue with exenatide because of the need to eat within 60 minutes of taking a dose.

Concerns about self-injecting also can be addressed by showing patients the pen injection device and its small-gauge needle and instructing them in its use. Having a patient self-inject the first dose in the office can relieve much anxiety. Patients often comment about how easy and painless it is to inject themselves. One caution, however, is that if a patient self-injects a dose of exenatide in the office, he or she must be reminded of the need to eat within the next hour.

**Case 1**

During your discussion with this building contractor, you begin to talk about the GLP-1 agonists and DPP-4 inhibitors as treatment options. You begin to discuss the need to self-inject the GLP-1 agonist, when he interrupts you and tells you that he does not want to hear anything about insulin or other medications that would require him to self-inject, because his work environment and schedule would make this impossible.
DISTINGUISHING AMONG INCREDIN-BASED THERAPIES

This comment highlights the importance of talking openly with patients to help them make good decisions about their health. Discussions often focus on the anticipated benefits of medications, but as we know, there are risks associated with every medication choice. Initially discussing risks with this patient could avoid having her return to the office angry with you for not warning her before she began taking the medication.

In this situation, as part of your discussion about liraglutide, you could refer her to the manufacturer’s Web site for information about the Risk Evaluation and Mitigation Strategy (REMS) program for liraglutide, sitagliptin, and saxagliptin. You also could provide her with the patient medication guide included with the program. REMS programs have been implemented for several glucose-lowering medications, since implementation of the REMS program by the US Food and Drug Administration (FDA) in 2007; these include exenatide, liraglutide, pioglitazone with or without glimepiride, rosiglitazone with or without glimepiride, and sitagliptin with or without metformin. Medication guides and other information are available online from the FDA at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm.

Medication cost

Case 3

You continue your discussion with this 68-year-old part-time librarian about the benefits and risks of insulin, a thiazolidinedione, and a glinide, as well as a GLP-1 agonist and a DPP-4 inhibitor. Suddenly she asks you how much these medications cost.

The cost of health care in general and medications in particular continue to dominate discussions. This is especially true for medications that have arrived on the market more recently, including the GLP-1 agonists and the DPP-4 inhibitors, which range in cost from about $7 to $14 per day.3–12 These agents, however, may be covered by health insurance, so cost to the patient may be limited to copays. The lower risk of hypoglycemia observed with the GLP-1 agonists and DPP-4 inhibitors compared with some other glucose-lowering therapies may make it possible to perform self-monitoring of blood glucose less frequently, but this is an individual patient issue.

Although it may be difficult or uncomfortable to talk about the costs of treatment, it has a great impact on medication adherence and overall treatment satisfaction. In this case, in addition to discussing insurance coverage and what she can afford, you should also talk with the patient about ways the cost of her medications might be reduced.

While no generic formulations are available for exenatide, liraglutide, saxagliptin, or sitagliptin, each manufacturer offers a prescription assistance program. Patients should also be encouraged to check manufacturers’ Web sites for available coupons or discount programs.

With this patient, you also might talk about how different medications can affect total cost of her diabetes treatment differently. Limited retrospective analyses suggest that compared with glimepiride, liraglutide reduces the total cost of care, including care for ocular events and neuropathy leading to amputation.13 Other studies indicate that the overall cost of care with exenatide is lower than with insulin glargine,14 including care for hypoglycemia-related events.15

Summary

Working closely with patients and providing ongoing education, ideally in conjunction with a diabetes care team, can help ensure that the best treatment options are selected for an individual patient and that the patient is capable of effective self-management.

References

Self-management resources for patients with T2DM

American Association of Clinical Endocrinologists (AACE)
904-353-7878, www.aace.com

American Association of Diabetes Educators (AADE)
800-338-3633, www.aadenet.org

American Diabetes Association® (ADA)
800-342-2383, www.diabetes.org

Diabetes and Cardiovascular Disease Fact Sheet

Joslin Diabetes Center

National Diabetes Education Program (NDEP)-Centers for Disease Control (CDC)
www.cdc.gov/team-ndep

NDEP-National Institutes of Health (NIH)
www.ndep.nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
www.niddk.nih.gov

MAGAZINE
Diabetes Self-Management magazine
www.diabetesselfmanagement.com

NUTRITION AND EXERCISE
American Dietetic Association (ADA)
800-877-1600, www.eatright.org

Diabetes Exercise and Sports Association
www.diabetes-exercise.org

Everyday Health™ Network
www.diabetic-recipes.com

National Center for Overcoming Overeating
www.overcomingovereating.com

US Department of Agriculture (USDA) National Nutrient Database
www.nal.usda.gov/fnic/foodcomp/search